You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
三生國健(688336.SH):重組抗IL-4Rα人源化單抗注射液獲批臨牀
格隆匯 09-22 15:58

格隆匯 9 月 22日丨三生國健(688336.SH)公佈,近日,公司產品重組抗IL-4Rα人源化單克隆抗體注射液(研發代號:611)收到國家藥監局核准簽發的《藥物臨牀試驗批准通知書》,並將於近期開展臨牀試驗。另外,該產品在美國臨牀I期試驗近日完成首例受試者入組。

重組抗IL-4Rα人源化單克隆抗體注射液(611)是公司自主研發設計、篩選的人源化抗IL-4Rα單克隆抗體,具有全新的氨基酸序列。其能夠通過特異性的結合IL-4Rα,阻斷IL-4和IL-13的信號傳導達到緩解特應性皮炎等疾病的作用。

截止2020年6月30日,公司現階段針對該新藥累計研發投入為人民幣約4406.41萬元(未經審計)。

截止公告日,於全球上市的IL-4Rα靶點的單克隆抗體藥品為Dupixent(Dupilumab)。賽諾菲2019年財報顯示:Dupixent®在全球實現銷售額20.74億歐元,同比增長163.2%。Dupixent(中文商品名達必妥)已於2020年6月在中國境內上市。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account